LUNELLE Drug Patent Profile

Which patents cover Lunelle, and when can generic versions of Lunelle launch?

Lunelle is a drug marketed by Pharmacia And Upjohn and is included in one NDA.

The generic ingredient in LUNELLE is estradiol cypionate; medroxyprogesterone acetate. There is one drug master file entry for this compound. Additional details are available on the estradiol cypionate; medroxyprogesterone acetate profile page.

Summary for LUNELLE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	5
Clinical Trials:	1
Patent Applications:	18
DailyMed Link:	LUNELLE at DailyMed

Recent Clinical Trials for LUNELLE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sun Pharmaceutical Industries Limited	Phase 1/Phase 2

See all LUNELLE clinical trials

US Patents and Regulatory Information for LUNELLE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacia And Upjohn	LUNELLE	estradiol cypionate; medroxyprogesterone acetate	INJECTABLE;INTRAMUSCULAR	020874-001	Oct 5, 2000		DISCN	Yes	No

Lunelle Market Dynamics, Financial Trajectory, Patent Status, and Commercial Outlook

Last updated: September 11, 2026

Lunelle was a monthly injectable hormonal contraceptive containing medroxyprogesterone acetate 25 mg and estradiol cypionate 5 mg. It was developed for monthly contraception but did not establish a durable U.S. commercial franchise. The product is no longer an active U.S. growth asset, has no meaningful publicly reported standalone revenue, and has limited current patent or regulatory value. Its commercial decline reflects competition from oral contraceptives, long-acting reversible contraception, depot medroxyprogesterone acetate, transdermal systems, vaginal rings, and later generic products.

What was Lunelle and how did the drug work?

Lunelle Monthly Contraceptive Injection combined a progestin and an estrogen in a once-monthly intramuscular injection.

Attribute	Lunelle
Active ingredients	Medroxyprogesterone acetate and estradiol cypionate
Strength	25 mg medroxyprogesterone acetate plus 5 mg estradiol cypionate
Route	Intramuscular injection
Intended dosing	Once monthly
Therapeutic category	Hormonal contraception
U.S. sponsor history	Pharmacia and related corporate entities
Current U.S. status	Discontinued from commercial use
Current revenue profile	No separately reported material revenue

Lunelle prevented ovulation and altered cervical mucus and the endometrium. The monthly schedule was intended to offer an alternative to daily oral contraception and the three-month dosing interval of Depo-Provera.

The product had a pharmacological advantage over daily pills for patients seeking monthly dosing. Its commercial limitations included the need for a clinic-administered injection, estrogen-related contraindications, irregular bleeding, and competition from contraceptive methods with longer duration or more convenient administration.

When did Lunelle lose exclusivity and commercial momentum?

Lunelle did not develop a long commercial life in the U.S. market. Its market trajectory can be summarized as follows:

Period	Commercial development
Late 1990s to early 2000s	U.S. regulatory introduction and initial commercialization
Early 2000s	Marketed within Pharmacia’s women’s health portfolio
2003	Pfizer acquired Pharmacia, transferring the product into Pfizer’s portfolio
Mid-2000s	Competition intensified from oral contraceptives, Depo-Provera, implants, intrauterine systems, patches, and rings
Late 2000s	U.S. commercial availability ended
2010s onward	No material U.S. sales franchise or active development program

Public sources do not establish a reliable, separately reported Lunelle revenue series. Pfizer’s financial reporting aggregated products into broader business segments and did not disclose Lunelle sales as an individual line item. The product’s commercial contribution was therefore likely immaterial relative to Pfizer’s major branded medicines.

What is the FDA regulatory status of Lunelle?

Lunelle is not an active U.S. commercial product. FDA drug-product records classify products that have been discontinued, but discontinuation does not necessarily mean that FDA withdrew the product’s approval for safety or efficacy reasons.

The product should be distinguished from an FDA safety withdrawal. Available public regulatory information does not establish a major FDA action alleging that Lunelle was unsafe or ineffective. The more relevant commercial event was the end of marketing and supply in the United States.

Was Lunelle voluntarily discontinued?

The U.S. product was discontinued from commercial distribution. Public information does not support treating the discontinuation as a product recall or a formal FDA withdrawal for safety reasons.

Potential commercial factors included:

• Limited physician and patient demand for a clinic-administered monthly injection.
• Competition from lower-cost and better-known contraceptive products.
• Manufacturing and supply economics for a relatively small-volume injectable.
• Estrogen-related prescribing restrictions.
• Availability of long-acting reversible contraceptives with longer duration.
• Lack of a differentiated reimbursement position.

What patents protected Lunelle?

Lunelle’s current patent estate does not appear to provide an active commercial barrier in the United States.

The active ingredients were established hormonal compounds rather than newly discovered molecular entities. Any protection would have depended primarily on formulation, combination, dosing, delivery, or manufacturing claims. Those forms of protection are typically shorter-lived or easier to design around than composition-of-matter protection for a new chemical entity.

Patent category	Relevance to Lunelle
Composition of matter	Limited, because both active ingredients were previously known
Combination formulation	Potential historical protection for the two-hormone combination
Injectable dosage form	Possible historical protection for suspension, concentration, or delivery parameters
Method of contraception	Potential use claims, but generally vulnerable to prior-art and obviousness challenges
Manufacturing process	Possible process protection, with limited current value after product discontinuation
Current Orange Book barrier	No material active barrier identified

A definitive patent-by-patent analysis would require historical Orange Book editions, FDA approval records, assignment records, and global patent databases. Current commercial evidence does not indicate that an unexpired U.S. patent materially constrains generic entry.

Were there Paragraph IV challenges to Lunelle?

No significant public Paragraph IV litigation involving Lunelle is widely reported.

That outcome is commercially logical. Paragraph IV litigation generally requires a market opportunity large enough to justify the cost of invalidity, noninfringement, and regulatory litigation. Lunelle’s limited sales, discontinued status, and absence of an active U.S. franchise reduced the incentive for a generic manufacturer to pursue a contested launch.

The absence of a public Paragraph IV case should not be interpreted as evidence of a strong patent estate. It is more consistent with the product’s limited remaining market value.

How did Lunelle compare with competing contraceptives?

Lunelle competed across several contraceptive categories rather than against one direct substitute.

Product or class	Dosing interval	Commercial advantage versus Lunelle
Oral contraceptives	Daily	Established prescribing behavior and broad generic availability
Depo-Provera	About every three months	Fewer annual injections
Transdermal patch	Weekly	Self-administration
Vaginal ring	Monthly	Monthly schedule without an injection
Hormonal IUD	Several years	Long duration and high contraceptive effectiveness
Implant	Several years	Very low user-maintenance burden
Copper IUD	Several years	Nonhormonal option
Lunelle	Monthly	Combined hormonal injection

The monthly schedule did not create enough differentiation to offset the burden of an injection administered by a health professional. The vaginal ring offered a comparable monthly rhythm with greater user control, while implants and intrauterine systems reduced dosing frequency substantially.

What formulation and manufacturing barriers affected Lunelle?

Lunelle required a sterile injectable suspension containing two hormonal agents with different physicochemical properties. The manufacturing process likely required controls over:

• Particle size and suspension uniformity.
• Sterility and microbial control.
• Dose homogeneity.
• Container closure integrity.
• Injectable stability.
• Resuspension and syringeability.
• Compatibility between the active ingredients and excipients.

These requirements can create technical barriers for a generic injectable. They do not, however, guarantee commercial exclusivity. Once demand falls, the fixed cost of manufacturing validation, sterile filling, regulatory submissions, and supply-chain maintenance can exceed the expected return.

The product’s manufacturing economics were weaker than those of high-volume injectable products. A competitor would have needed to invest in development and manufacturing capacity for a market with limited visible demand and several established alternatives.

Did Pfizer license or divest Lunelle?

Lunelle was associated with Pharmacia before Pfizer acquired Pharmacia in 2003. Pfizer’s acquisition transferred the product into its broader portfolio. Publicly available corporate reporting does not show a major later licensing transaction that created a new commercial platform around Lunelle.

No material current licensing market appears to exist for the brand in the United States. Any residual value would more likely relate to historical formulation know-how, regulatory documentation, or rights in selected foreign markets than to U.S. branded sales.

What litigation affected Lunelle?

No major publicly reported patent litigation appears to have shaped the product’s U.S. commercial trajectory.

The lack of significant litigation is consistent with:

• Low anticipated generic-entry value.
• Limited remaining sales.
• No widely reported active patent dispute.
• Discontinuation before a substantial generic market developed.
• A crowded contraceptive market with stronger commercial alternatives.

There is also no prominent public settlement agreement associated with a Paragraph IV challenge to Lunelle.

What was Lunelle’s financial trajectory?

Lunelle’s financial trajectory was a short-lived branded-product cycle rather than a long-duration specialty pharmaceutical franchise.

Launch and early commercialization

The product entered a market with established hormonal contraceptives and strong physician familiarity with oral contraceptives and depot injections. Its monthly injection schedule offered differentiation, but the product required office administration and did not create a durable pricing premium.

Portfolio absorption after the Pharmacia acquisition

After Pfizer acquired Pharmacia, Lunelle became a small product within a much larger women’s health and pharmaceutical portfolio. Pfizer did not disclose separate Lunelle revenue, prescription volume, gross margin, or operating profit.

Decline and discontinuation

The product’s economics likely deteriorated as alternatives expanded and the cost of maintaining a sterile injectable product remained relatively high. Once sales fell below a viable threshold, continued manufacturing and regulatory maintenance became difficult to justify.

Current value

Lunelle has no identifiable standalone public-market value. The brand is not a significant contributor to Pfizer revenue, and there is no clear active U.S. licensing or generic opportunity.

Financial indicator	Publicly supportable conclusion
Peak annual revenue	Not separately disclosed
Current annual revenue	No material U.S. revenue identified
Net price trend	No reliable public product-level series
Gross margin	Not disclosed
U.S. market share	No current meaningful share
Pipeline value	None evident
Licensing value	Limited and likely jurisdiction-specific

What generic entry risks exist for Lunelle?

Generic competition is not the principal current risk because the branded product has already lost commercial relevance. The more important issue is whether a manufacturer could profitably revive or substitute the product.

A generic or follow-on injectable would face:

1. A small and uncertain patient base.
2. Competition from established contraceptive products.
3. Sterile manufacturing and quality-control costs.
4. Potential clinical or bioequivalence complexity.
5. Reimbursement pressure.
6. Limited physician demand for monthly injections.

The absence of a viable commercial market can be a stronger deterrent than patent protection. A theoretically open market may remain unattractive if annual sales cannot support development and manufacturing costs.

How strong is the Lunelle patent estate?

The Lunelle patent estate is commercially weak today.

Its historical protection may have covered aspects of the combination, injectable formulation, dosing regimen, or manufacturing process. Those claims would have had limited remaining life because the product entered the market more than two decades ago. The absence of a visible active U.S. franchise, major litigation, or current Orange Book dispute indicates that patent rights no longer drive market access.

From an investment or licensing perspective, Lunelle should be assessed as a discontinued-product and historical-technology matter, not as an active exclusivity platform.

What geographic markets still matter?

The United States is not a meaningful current market for Lunelle. Any remaining geographic value would depend on whether related monthly injectable contraceptive products remain marketed under different brands or rights holders in selected countries.

Global evaluation would require country-level confirmation of:

• Marketing authorization status.
• Local brand ownership.
• Patent and supplementary protection certificate status.
• Manufacturing rights.
• Distribution agreements.
• Tender or reimbursement access.
• Local contraceptive guidelines.

The U.S. discontinuation does not automatically establish that every foreign authorization or brand right ended at the same time.

Key Takeaways

• Lunelle was a monthly injectable combination of medroxyprogesterone acetate and estradiol cypionate.
• Its U.S. commercial trajectory was limited and ended after the product failed to establish a durable position against oral, depot, transdermal, vaginal, implant, and intrauterine contraceptives.
• Pfizer inherited Lunelle through its acquisition of Pharmacia but did not report standalone product revenue.
• No material current U.S. Orange Book or patent barrier is evident.
• No major public Paragraph IV litigation or settlement appears to have affected the product.
• The primary barrier to a generic or revived product is weak market economics, not a strong surviving patent estate.
• Lunelle has negligible current U.S. revenue and limited licensing or investment value.

FAQs about Lunelle market dynamics and exclusivity

Is Lunelle still available in the United States?

No. Lunelle is no longer an active U.S. commercial contraceptive product.

Did Lunelle have a generic equivalent?

No widely used U.S. generic equivalent established a material market after Lunelle’s commercial discontinuation.

Was Lunelle the same as Depo-Provera?

No. Lunelle was a monthly combined estrogen-progestin injection. Depo-Provera uses depot medroxyprogesterone acetate alone and is generally administered at a three-month interval.

Did Lunelle generate significant revenue for Pfizer?

Pfizer did not report Lunelle revenue separately. Available corporate reporting does not indicate that the product was a material contributor to Pfizer’s consolidated financial results.

Is Lunelle a viable patent or licensing acquisition target?

Its U.S. value is limited. A potential transaction would require evidence of active foreign rights, regulatory approvals, manufacturing assets, or a defined market for a related monthly injectable contraceptive.

References

1. Pfizer Inc. (2003-2008). Annual reports and Form 10-K filings. Pfizer Investor Relations.

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (n.d.). FDA drug product database and discontinued drug products. https://www.accessdata.fda.gov/

5. U.S. Food and Drug Administration. (2004). Lunelle Monthly Contraceptive Injection prescribing information. FDA-approved labeling.